China’s Center for Drug Evaluation of the National Medical Products Administration approved Yutiq for chronic noninfectious uveitis affecting the posterior segment, EyePoint Pharmaceuticals and OcuMension announced in a press release.
Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg is the first drug approved for commercialization in China based entirely on real-world data and the first drug approved for commercial use in OcuMension’s pipeline, the release said.
“Yutiq’s approval in China marks an important milestone for EyePoint and OcuMension’s shared